-
Beyond the Trials: How Patients Experience 12 Months of Targeted Therapy
Read time: 2 minutes. Clinical trials have transformed the treatment landscape for people with ALK- and EGFR-positive non-small cell lung cancer (NSCLC). But while clinical trials -
Breaking Down Barriers: Project ASCENT Boosts Lung Cancer Screening in Hispanic/Latin Communities
Read time: 2 minutes. Lung cancer remains the leading cause of cancer death, and for many communities, barriers like culture, language, and access make lifesaving screening even -
Closing the Loop: Sharing Research Results Back with the Lung Cancer Community
Read time: 2 minutes. When patients and caregivers participate in lung cancer research, they are generously offering their time, experiences, and personal stories to improve care -
Understanding the Patient Experience in EGFR-Positive Lung Cancer
Over the past two decades, treatment for EGFR-positive lung cancer has transformed dramatically. The introduction of tyrosine kinase inhibitors (TKIs) has led to major improvements
